Abbott Laboratories (ABT)vs20/20 Biolabs, Inc. Common Stock (AIDX)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
AIDX
20/20 Biolabs, Inc. Common Stock
$1.64
-17.59%
HEALTHCARE · Cap: $20.59M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 2169757% more annual revenue ($44.33B vs $2.04M). ABT leads profitability with a 14.7% profit margin vs -1.6%. ABT earns a higher WallStSmart Score of 51/100 (C-).
ABT
Buy51
out of 100
Grade: C-
AIDX
Avoid18
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Intrinsic value data unavailable for AIDX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
15.8% revenue growth
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Trading at 164.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : AIDX
The strongest argument for AIDX centers on Revenue Growth. Revenue growth of 15.8% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : AIDX
The primary concerns for AIDX are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABT profiles as a value stock while AIDX is a growth play — different risk/reward profiles.
ABT carries more volatility with a beta of 0.74 — expect wider price swings.
AIDX is growing revenue faster at 15.8% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (51/100 vs 18/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →20/20 Biolabs, Inc. Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
20/20 Biolabs, Inc. (ticker: AIDX) is a biotechnology company focused on providing innovative solutions for genomic research and diagnostics. The company specializes in delivering advanced laboratory services that enhance the accuracy and efficiency of genetic testing, catering to both clinical and research markets. With a commitment to leveraging cutting-edge technologies, 20/20 Biolabs aims to redefine the standards of molecular diagnostics and contribute significantly to the advancement of personalized medicine. As the demand for genomic data continues to rise, the company's strategic initiatives position it well for growth in this rapidly evolving sector.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?